Call Options

17 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$62.0 - $79.01 $49,600 - $63,208
800 Added 1.6%
50,700 $3.7 Million
Q2 2024

Aug 14, 2024

SELL
$22.0 - $69.71 $46,200 - $146,391
-2,100 Reduced 4.04%
49,900 $3.34 Million
Q1 2024

May 15, 2024

BUY
$25.72 - $29.94 $1.12 Million - $1.31 Million
43,700 Added 526.51%
52,000 $1.41 Million
Q4 2023

Feb 14, 2024

BUY
$23.42 - $31.74 $194,386 - $263,442
8,300 New
8,300 $257,000
Q2 2021

Aug 06, 2021

SELL
$24.17 - $36.01 $166,773 - $248,469
-6,900 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$32.28 - $44.3 $222,732 - $305,670
6,900 New
6,900 $223,000
Q2 2020

Aug 13, 2020

SELL
$14.11 - $29.42 $334,407 - $697,254
-23,700 Closed
0 $0
Q1 2020

May 11, 2020

SELL
$13.63 - $33.98 $213,991 - $533,486
-15,700 Reduced 39.85%
23,700 $406,000
Q4 2019

Feb 12, 2020

BUY
$16.12 - $24.98 $327,236 - $507,094
20,300 Added 106.28%
39,400 $923,000
Q3 2019

Nov 14, 2019

SELL
$15.49 - $25.78 $38,725 - $64,450
-2,500 Reduced 11.57%
19,100 $349,000
Q2 2019

Aug 20, 2019

BUY
$23.0 - $32.19 $59,800 - $83,694
2,600 Added 13.68%
21,600 $553,000
Q1 2019

May 15, 2019

BUY
$13.91 - $31.15 $264,290 - $591,850
19,000 New
19,000 $552,000
Q4 2018

Feb 14, 2019

SELL
$11.6 - $18.7 $451,240 - $727,430
-38,900 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$18.95 - $28.08 $361,945 - $536,328
19,100 Added 96.46%
38,900 $787,000
Q1 2018

May 15, 2018

SELL
$21.69 - $32.99 $15,183 - $23,093
-700 Reduced 3.41%
19,800 $446,000
Q4 2017

Feb 14, 2018

SELL
$26.43 - $31.78 $2.98 Million - $3.59 Million
-112,900 Reduced 84.63%
20,500 $639,000
Q3 2017

Nov 15, 2017

BUY
$11.61 - $31.21 $1.55 Million - $4.16 Million
133,400
133,400 $4.16 Million

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $8.98B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.